Published in Oncoimmunology on December 01, 2012
Current State of Animal (Mouse) Modeling in Melanoma Research. Cancer Growth Metastasis (2015) 0.91
Tumor-infiltrating dendritic cells in cancer pathogenesis. J Immunol (2015) 0.87
A novel therapy for melanoma developed in mice: transformation of melanoma into dendritic cells with Listeria monocytogenes. PLoS One (2015) 0.78
Loss of MAPK-activated protein kinase 2 enables potent dendritic cell-driven anti-tumour T cell response. Sci Rep (2017) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
NOD/SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood (2002) 7.78
Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol (2002) 7.60
Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J Immunol (1995) 5.75
Human melanoma-initiating cells express neural crest nerve growth factor receptor CD271. Nature (2010) 5.05
The origin and development of nonlymphoid tissue CD103+ DCs. J Exp Med (2009) 4.79
Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol (2009) 4.51
Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nat Med (2007) 4.39
Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol (2001) 4.23
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol (2008) 3.93
Characterization of human DNGR-1+ BDCA3+ leukocytes as putative equivalents of mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.84
Human tissues contain CD141hi cross-presenting dendritic cells with functional homology to mouse CD103+ nonlymphoid dendritic cells. Immunity (2012) 3.58
Tumor-infiltrating DCs suppress nucleic acid-mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1. Nat Immunol (2012) 3.57
Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med (2004) 3.55
Toll-like receptor expression in murine DC subsets: lack of TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol (2003) 3.39
The CD8+ dendritic cell subset. Immunol Rev (2010) 3.32
The XC chemokine receptor 1 is a conserved selective marker of mammalian cells homologous to mouse CD8alpha+ dendritic cells. J Exp Med (2010) 3.20
Origin and development of dendritic cells. Immunol Rev (2010) 2.90
CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells. J Exp Med (2009) 2.75
Antigen-presentation properties of plasmacytoid dendritic cells. Immunity (2008) 2.57
Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. Cancer Res (2012) 2.48
Langerhans cells and more: langerin-expressing dendritic cell subsets in the skin. Immunol Rev (2010) 2.44
Antigen crosspresentation by human plasmacytoid dendritic cells. Immunity (2007) 2.42
Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med (2010) 2.21
Prognostic and predictive impact of intra- and peritumoral immune infiltrates. Cancer Res (2011) 2.16
Dendritic cell control of tolerogenic responses. Immunol Rev (2011) 2.13
Organ selectivity for implantation survival and growth of B16 melanoma variant tumor lines. J Natl Cancer Inst (1976) 2.09
Interleukin 12-dependent interferon gamma production by CD8alpha+ lymphoid dendritic cells. J Exp Med (1999) 2.05
Infection-mimicking materials to program dendritic cells in situ. Nat Mater (2009) 2.00
Origin and functional heterogeneity of non-lymphoid tissue dendritic cells in mice. Immunol Rev (2010) 1.99
Tumor-infiltrating regulatory dendritic cells inhibit CD8+ T cell function via L-arginine metabolism. Cancer Res (2009) 1.99
Signaling by myeloid C-type lectin receptors in immunity and homeostasis. Annu Rev Immunol (2012) 1.95
Studying the mononuclear phagocyte system in the molecular age. Nat Rev Immunol (2011) 1.93
Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. Cancer Res (2008) 1.92
Transgenic mouse model for skin malignant melanoma. Oncogene (1998) 1.90
Chemokines and cancer: migration, intracellular signalling and intercellular communication in the microenvironment. Biochem J (2008) 1.83
Malignant melanoma: prevention, early detection, and treatment in the 21st century. CA Cancer J Clin (2000) 1.79
Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J Immunol (1993) 1.78
In vivo function of Langerhans cells and dermal dendritic cells. Trends Immunol (2010) 1.71
Comparative genomics as a tool to reveal functional equivalences between human and mouse dendritic cell subsets. Immunol Rev (2010) 1.70
Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69
Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. J Immunol (2006) 1.68
Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol (2005) 1.67
In situ regulation of DC subsets and T cells mediates tumor regression in mice. Sci Transl Med (2009) 1.65
Features of the dendritic cell lineage. Immunol Rev (2010) 1.58
DC subsets in positive and negative regulation of immunity. Immunol Rev (2010) 1.56
Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med (2009) 1.54
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 1.53
Intratumoral neutrophils and plasmacytoid dendritic cells indicate poor prognosis and are associated with pSTAT3 expression in AJCC stage I/II melanoma. Cancer (2011) 1.53
Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother (1997) 1.47
Induction of potent antitumor immunity by in situ targeting of intratumoral DCs. J Clin Invest (2004) 1.44
Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol (2010) 1.42
TLR signalling regulated antigen presentation in dendritic cells. Curr Opin Immunol (2010) 1.38
Characterization of an immediate splenic precursor of CD8+ dendritic cells capable of inducing antiviral T cell responses. J Immunol (2009) 1.37
The role of dendritic cell precursors in tumour vasculogenesis. Br J Cancer (2005) 1.35
High endothelial venules (HEVs) in human melanoma lesions: Major gateways for tumor-infiltrating lymphocytes. Oncoimmunology (2012) 1.28
Tumor-infiltrating programmed death receptor-1+ dendritic cells mediate immune suppression in ovarian cancer. J Immunol (2011) 1.28
Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol (2010) 1.28
Activation of p38 mitogen-activated protein kinase drives dendritic cells to become tolerogenic in ret transgenic mice spontaneously developing melanoma. Clin Cancer Res (2009) 1.28
Density of DC-LAMP(+) mature dendritic cells in combination with activated T lymphocytes infiltrating primary cutaneous melanoma is a strong independent prognostic factor. Cancer Immunol Immunother (2007) 1.28
Local administration of PF-3512676 CpG-B instigates tumor-specific CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res (2008) 1.24
Intratumoral cytokines/chemokines/growth factors and tumor infiltrating dendritic cells: friends or enemies? Cancer Metastasis Rev (2006) 1.24
Melanoma-induced immunosuppression and its neutralization. Semin Cancer Biol (2012) 1.23
Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions. Eur J Immunol (2003) 1.22
TLR7 enables cross-presentation by multiple dendritic cell subsets through a type I IFN-dependent pathway. Blood (2011) 1.21
Metastatic melanoma secreted IL-10 down-regulates CD1 molecules on dendritic cells in metastatic tumor lesions. Am J Pathol (2004) 1.16
Tumoricidal properties of mouse macrophages activated with mediators from rat lymphocytes stimulated with concanavalin A. Cancer Res (1976) 1.15
Immunodeficient mouse strains display marked variability in growth of human melanoma lung metastases. Clin Cancer Res (2009) 1.12
Subsets of migrating intestinal dendritic cells. Immunol Rev (2010) 1.12
Characterization of circulating dendritic cells in melanoma: role of CCR6 in plasmacytoid dendritic cell recruitment to the tumor. J Invest Dermatol (2010) 1.12
Dendritic cells: biology of the skin. Contact Dermatitis (2009) 1.11
Tumor-infiltrating dendritic cells are potent antigen-presenting cells able to activate T cells and mediate tumor rejection. J Immunol (2006) 1.10
CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ. J Immunol (2001) 1.09
Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother (2008) 1.08
Selective accumulation of mature DC-Lamp+ dendritic cells in tumor sites is associated with efficient T-cell-mediated antitumor response and control of metastatic dissemination in melanoma. Cancer Res (2004) 1.07
Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J (2009) 1.06
Anticancer TLR agonists on the ropes. Nat Rev Drug Discov (2012) 1.05
Local administration of granulocyte/macrophage colony-stimulating factor increases the number and activation state of dendritic cells in the sentinel lymph node of early-stage melanoma. Cancer Res (2004) 0.98
Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol (2010) 0.97
A mouse model of melanoma driven by oncogenic KRAS. Cancer Res (2010) 0.96
Differential expression of pathogen-recognition molecules between dendritic cell subsets revealed by plasma membrane proteomic analysis. Mol Immunol (2010) 0.95
Cell-associated double-stranded RNA enhances antitumor activity through the production of type I IFN. J Immunol (2006) 0.95
Mouse melanoma models and cell lines. Pigment Cell Melanoma Res (2010) 0.92
Differentiation of human tumour-associated dendritic cells into endothelial-like cells: an alternative pathway of tumour angiogenesis. Scand J Immunol (2007) 0.91
Low-dose mistletoe lectin-I reduces melanoma growth and spread in a scid mouse xenograft model. Br J Cancer (2007) 0.91
Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice. J Immunol (2010) 0.90
Antigen processing and MHC-II presentation by dermal and tumor-infiltrating dendritic cells. J Immunol (2009) 0.90
Deciphering the message broadcast by tumor-infiltrating dendritic cells. Am J Pathol (2012) 0.90
Immunomodulatory cytokines as therapeutic agents for melanoma. Immunotherapy (2011) 0.88
Murine melanoma-infiltrating dendritic cells are defective in antigen presenting function regardless of the presence of CD4CD25 regulatory T cells. PLoS One (2011) 0.88
Antigen presentation by dendritic cells in tumors is disrupted by altered metabolism that involves pyruvate kinase M2 and its interaction with SOCS3. Cancer Res (2009) 0.87
Re-inventing intratumoral immunotherapy for melanoma. Immunotherapy (2011) 0.86
Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res (2010) 0.86
In situ recruitment of antigen-presenting cells by intratumoral GM-CSF gene delivery. Cancer Immunol Immunother (2003) 0.85
The interplay between surfaces and soluble factors define the immunologic and angiogenic properties of myeloid dendritic cells. BMC Immunol (2011) 0.85
Melanoma-infiltrating dendritic cells induce protective antitumor responses mediated by T cells. Melanoma Res (2007) 0.85
Tumor-specific CD8+ T cell reactivity in the sentinel lymph node of GM-CSF-treated stage I melanoma patients is associated with high myeloid dendritic cell content. Clin Cancer Res (2006) 0.84
Recruitment and differentiation of conventional dendritic cell precursors in tumors. J Immunol (2009) 0.84
Regulation of the trafficking of tumour-infiltrating dendritic cells by chemokines. Semin Cancer Biol (2004) 0.84
The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9. Nat Immunol (2006) 5.83
Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs by Trif-dependent and Trif-independent pathways. Nat Immunol (2003) 4.15
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
Dendritic cell programming by cytomegalovirus stunts naive T cell responses via the PD-L1/PD-1 pathway. J Immunol (2008) 1.27
Anti-T-cell Ig and mucin domain-containing protein 1 antibody decreases TH2 airway inflammation in a mouse model of asthma. J Allergy Clin Immunol (2005) 1.19
Protein kinase C-theta is an early survival factor required for differentiation of effector CD8+ T cells. J Immunol (2005) 1.17
Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res (2011) 1.03
Cutting edge: merocytic dendritic cells break T cell tolerance to beta cell antigens in nonobese diabetic mouse diabetes. J Immunol (2010) 0.97
Cross-presentation of cell-associated antigens by mouse splenic dendritic cell populations. Front Immunol (2012) 0.93
Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice. J Immunol (2010) 0.90
Nab2 regulates secondary CD8+ T-cell responses through control of TRAIL expression. Blood (2011) 0.84
IL-2 gets with the program. Nat Immunol (2006) 0.83
Interleukin-2 rescues helpless effector CD8+ T cells by diminishing the susceptibility to TRAIL mediated death. Immunol Lett (2011) 0.82
Harnessing dendritic cells for tumor antigen presentation. Cancers (Basel) (2011) 0.78
Breaking T cell tolerance to beta cell antigens by merocytic dendritic cells. Cell Mol Life Sci (2011) 0.77
CD4 cell-secreted, posttranslationally modified cytokine GIF suppresses Th2 responses by inhibiting the initiation of IL-4 production. Proc Natl Acad Sci U S A (2008) 0.76
Immunosuppression: learning from the masters. Expert Rev Clin Immunol (2007) 0.76
Respond to "No antigen-presentation defect in Unc93b1(3d/3d) (3d) mice". Nat Immunol (2013) 0.75